Roche: approval in spinal muscular atrophy

(CercleFinance.com) - Swiss healthcare giant Roche has announced that the US FDA has approved its Evrysdi (risdiplam) for the treatment of spinal muscular atrophy (SMA) in adults and children two months of age and older.


Evrysdi showed "clinically significant" improvements in motor function in two clinical trials in people of various ages and disease severity levels, including SMA types 1, 2 and 3.


Copyright (c) 2020 CercleFinance.com. All rights reserved.